Key Moments
- BioArctic AB signed a research and collaboration agreement with Eli Lilly and Company to pair its BrainTransporter platform with a Lilly neurodegeneration candidate, lifting BioArctic shares by more than 2%.
- The deal includes a $30 million upfront payment, potential milestone payments of up to $770 million, and tiered mid-single digit royalties on possible future global sales.
- This is BioArctic’s fourth collaboration involving BrainTransporter, while the company retains rights to use the platform outside the four existing agreements.
Deal Overview and Financial Terms
BioArctic AB announced that it has entered into a research and collaboration agreement with Eli Lilly and Company to integrate BioArctic’s BrainTransporter drug-delivery technology with an undisclosed Lilly investigational compound targeting neurodegenerative disease. Following the announcement, BioArctic’s share price moved higher by more than 2%.
Under the terms disclosed, BioArctic will receive an upfront payment of $30 million. In addition, the Stockholm-based company is eligible for further development and commercial milestone payments that could reach up to $770 million in total. The agreement also provides for tiered mid-single digit royalties on future global product sales if the combined product successfully reaches the market.
Responsibilities and Development Structure
Within the framework of the collaboration, BioArctic will be responsible for generating a new drug candidate that fuses its BrainTransporter technology with a proprietary Lilly molecule. Once this candidate is created, Eli Lilly will take over and hold full responsibility for global development and commercialization of the new therapy and any related products, according to BioArctic.
| Component | Description |
|---|---|
| Upfront payment | $30 million |
| Potential milestones | Up to $770 million |
| Royalties | Tiered mid-single digit royalties on global sales, if marketed |
| BioArctic role | Generate new candidate combining BrainTransporter with Lilly molecule |
| Lilly role | Global development and commercialization |
Management Commentary
BioArctic’s Chief Executive Officer, Gunilla Osswald, highlighted the strategic significance of the transaction, stating: “I’m excited by today’s announcement and proud that a large pharmaceutical company sees potential in our proprietary BrainTransporter technology. Lilly shares our ambition to do more for patients with severe neurological disorders, and this collaboration is a testament to that.”
Growing Partner Network for BrainTransporter
The Eli Lilly agreement marks the fourth partnership BioArctic has established involving its BrainTransporter platform. The company outlined prior arrangements that include:
- A research evaluation agreement with Eisai relating to BAN2802.
- A global license agreement with Bristol Myers Squibb covering BioArctic’s PyroGlutamate-amyloid-beta antibody program.
- An option, collaboration, and license agreement with Novartis.
Despite these arrangements, BioArctic stated that it retains all rights to deploy the BrainTransporter platform outside the scope defined by these four agreements. The company noted that the technology can be applied in multiple therapeutic areas to deliver biologics and other modalities to the brain.
BrainTransporter Platform and Blood-Brain Barrier Targeting
According to BioArctic, the BrainTransporter technology enables drugs to cross into the brain by engaging the transferrin receptor. The company indicated that this approach allows active transport of medicines across the blood-brain barrier, which can provide broader distribution within the brain. BioArctic said this may support enhanced therapeutic efficacy, an improved safety profile, and greater dosing convenience.
Background on Leqembi and Alzheimer’s Program
BioArctic stated that it invented Leqembi (lecanemab), which it describes as the world’s first therapy demonstrated to slow disease progression and reduce cognitive decline in patients with early Alzheimer’s disease. The company noted that Leqembi was developed in partnership with Eisai. Eisai is responsible for regulatory interactions and commercialization worldwide, according to BioArctic.
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
